AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05112705 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Proximal lower limb ultrasound
Description: Twice weekly proximal lower limb ultrasound
Study NCT04923451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Trans-cranial direct current stimulation (tDCS)
Description: 5 active sessions (1/day for 5 consecutive days) of tDCS (NeuroConn DC), active anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode, 2 mA, during 30 min will be performed
Study NCT04923451 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Trans-cranial direct current stimulation (tDCS)
Description: 5 placebo sessions (1/day for 5 consecutive days) of sham tDCS (NeuroConn DC), anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode during 30min will be performed
Study NCT05504525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca block
Description: Ultrasound guided fascia iliaca block done by palpation of anterior superior iliac spine to identify the inguinal crease, then place the ultrasound probe on it to identify the sartorius muscle. Sonographic anatomy will be identified, from superficial to deep, consisting of subcutaneous fat, the internal oblique muscle, the transverse abdominis muscle, the fascia iliaca covering the iliacus muscle and the iliacus muscle itself. The block needle will be advanced in out-of plane to puncture the fascia iliaca. With the needle tip just below the fascia iliaca, 2 ml of a local anesthetic will be injected to confirm the tip location. Once the proper position is confirmed, 40 ml of bupivacaine 0.25% will be injected superficial to the iliacus muscle and deep to the fascia iliaca.
Study NCT05504525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: The patients will receive anterior ultrasound guided quadratus lumborum block QLB in the lateral position. The transducer will be first placed in a parasagittal orientation 3-4 cm lateral to the midline and over the sacrum to identify the L5 transverse process. The probe will then rotated into a transverse orientation with slight medial and caudal angulation to obtain a transverse oblique view at L5 transverse process .The ultrasound probe will be tilted , so the lateral end of the probe will be more cranial than the medial side of the probe to avoid the acoustic shadow of the iliac crest. Identify the quadratus lumborum and psoas major and inject the local anesthetic above the QL
Study NCT01089179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01089179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT04311632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product
Study NCT04311632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression
Study NCT04311632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression
Study NCT04311632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression
Study NCT04311632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression
Study NCT04311632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression
Study NCT04311632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression
Study NCT04311632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Standard of Care induction therapy in solid organ transplantation
Study NCT05000762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Zinc
Description: Zinc gluconate 30 mg/day orally
Study NCT06319118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo + usual care, placebo 5 mg daily; 2.5mg 2 times daily, after breakfast and dinner.
Study NCT06319118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroergotine mesylate sustained-release tablets
Description: Dihydroergotine mesylate extended-release tablets + conventional treatment, dihydroergotine mesylate sustained-release tablets 5mg daily; 2.5mg 2 times daily, after breakfast and dinner.
Study NCT06098040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flash glucose monitoring continuous
Description: Group 2 (FGM continuous): will be asked to wear the sensor FreeStyle Libre2 for the FGM with the following frequency fashion continuously for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
Study NCT06098040 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: capillary blood test
Description: Group 1 (SMBG): will be asked to test capillary blood glucose as recommended by subjects' usual provider for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
Study NCT06098040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flash glucose monitoring intermittent
Description: Group 3 (FGM intermittent): will be asked to wear the sensor FreeStyle Libre2 for the FGM with the following frequency fashion 1 week off/2 weeks on for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
Study NCT04711005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (2R,6R)-Hydroxynorketamine hydrochloride
Description: (2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.
Study NCT04711005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.
Study NCT05926492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib plus chemotherapy
Description: Surufatinib: (1) for patients aged > 21 years old and ≤70 years old, surufatinib 200 mg, qd, oral, continuous administration; (2) For patients aged ≥2 years and ≤21 years, starting from the low dose of patient BSA (body surface area), Stevenson's formula developed according to the Chinese population was used: BSA = 0.0061H+0.0128W-0.1529 (H: BSA = 0.0061H+0.0128W-0.1529). Height /cm; W: body weight /kg); Chemotherapy : 1) Doxorubicin 60 mg/m2, or liposome doxorubicin 45mg/ m2, day 17; 2) Cisplatin: 100 mg/m2, day 15; 3) Ifosfamide; 2.5g/m2, day 8-12;~The above drugs were used in turn, and 30 days were regarded as a treatment cycle.
Study NCT05926492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 1) High-dose methotrexate : 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring), day 1 and 8; 2) Doxorubicin 60 mg/m2 or liposomal doxorubicin 45mg/ m2, day 17; 3) Cisplatin: 100 mg/m2, day 15;4) Ifosfamide; 2.5 g/m2, day 8-12.~The above drugs were used in turn, and 30 days were regarded as a treatment cycle.
Study NCT05952999 — intervention group
Intervention type: OTHER
Intervention: Digital Care Solution as supportive personalized care
Description: Patients will need to meet screening and inclusion criteria at time of enrollment. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
Study NCT05952999 — intervention group
Intervention type: OTHER
Intervention: Traditional Hospital Level Care
Description: Patients will be cared for in the inpatient setting for management of diseases that meet screening and inclusion criteria at time of enrollment for hospital at home. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
Study NCT05317351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Subjects randomized into arm 1 will undergo standard colonoscopy using a standard colonoscope
Study NCT05317351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Intelligence Aided Colonoscopy (GI Genius™)
Description: Subjects randomized into arm 2 will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)
Study NCT05317351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Artificial Intelligence Aided Colonoscopy (GI Genius™) and G-EYE® Balloon Aided Colonoscopy
Description: Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™).
Study NCT06389461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4th Ventricular Compression Technique
Description: The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator joins hands in a cupping position, with the pads of the 1st fingers forming a triangle. The pads of the 1st fingers make contact with the spinous processes of the 2nd and 3rd cervical vertebrae. The thenar eminences make contact with the occipital squama, avoiding contact with the occipito-mastoid sutures during 5 minutes.~A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.
Study NCT06389461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Therapy
Description: The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator places hands on the patient's shoulders during 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.
Study NCT05432089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: 24IU (12IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
Study NCT05432089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin
Description: 24IU (12IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
Study NCT06140862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calf muscle strengthening and streching
Description: lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
Study NCT06140862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: calf muscle strengthening and streching
Description: lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
Study NCT05147090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10mg daily
Study NCT05147090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Identical in appearance to empagliflozin 10mg daily
Study NCT05737199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475 (pembrolizumab)
Description: MK-3475 (pembrolizumab) 200mg IV every 3 weeks \[Q3W\] Treated for 2 years (35 cycles), or until PD, unacceptable toxicity, or study withdrawal.
Study NCT06133062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
Study NCT06133062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
Study NCT06133062 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: * 72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 66 CGE in 10 fractions for tumors >1 cm from the hepatic hilum, bowel, and heart.
Study NCT06338137 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Holmium Yag laser
Description: Use two laser energy low and high to reach the optimal setting for stone dusting
Study NCT05181293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Gaming App for Nutrition Intervention
Description: A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
Study NCT05905978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal donors predisposed by CXL
Description: Corneal donors predisposed by CXL and DALK procedure was conducted in patients
Study NCT05905978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal donors stored in corneal storage media
Description: Corneal donors stored in corneal storage media and DALK procedure was conducted in patients
Study NCT06098742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antareit
Description: A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake
Study NCT05724511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIYAIRI 588
Description: In the 3 months intervention, each subjects take 1g/package with meal, and 3 packages/day.
Study NCT04892849 — intervention group
Intervention type: OTHER
Intervention: Conventional Therapy acc. to prevailing clincal approved schemes
Description: The study is observational. The treatment-plan of the underlying disease remains unchanged. The treatment of the patient is according to the prevailing clinical approved schemes at the respective entities. Blood will be drawn from patients at several time points during and after RT and ICI for detailed immunomonitoring of the patients.
Study NCT05212870 — intervention group
Intervention type: OTHER
Intervention: assessment of cognitive level, pain catastrophe, physical activity level and quality of life
Description: assessment of cognitive level, pain catastrophe, physical activity level and quality of life
Study NCT04916691 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: EPSB for rib fractures
Description: EPSB for rib fractures
Study NCT04916691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Standard of care weight-based optimal Ropivacaine dosing for ESPB
Study NCT05133310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Combination of Simvastatin with Standard Chemotherapy scheme for acute lymphoblastic patients.
Study NCT06062342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FPI
Description: The FPI intervention will be conducted twice per month (across 21 months) in a zip code, and each event will last approximately 4-5 hours. At the event, participants will receive HIV testing, PrEP linkage (e.g., prescription) and knowledge, and condom and use/access.
Study NCT04937465 — intervention group
Intervention type: OTHER
Intervention: No intervention done
Description: No intervention was done. This was an observational study.
Study NCT06268756 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study NCT04143464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kyphosis-specific exercise class and kyphosis-specific exercise videos
Description: The kyphosis-specific exercise is based on the protocol published by Katzman and team in 2016. It includes warm-up, back muscle strength training, spine mobility training, spine alignment training, and stretching. The class will last around 60 minutes.~The exercise videos have the same content as the kyphosis-specific exercise class. The participants are asked to practice everyday at home following the videos.
Study NCT04963985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis Pill
Description: Oral
Study NCT05284526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
Description: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
Study NCT05284526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
Description: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
Study NCT05294289 — intervention group
Intervention type: OTHER
Intervention: Alpelisib
Description: There is no treatment allocation. Patients administered alpelisib by prescription that involved in Novartis' alpelisib managed access program will be enrolled
Study NCT05261698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Exercise Manual
Description: in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.
Study NCT05261698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT
Description: In this group patients will receive routine physical therapy including hot pack for 10 minutes, stretching, strengthening exercise and TENS at the end of each session.
Study NCT03507946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermawrap - combined 460nm, 633nm and 830nm LED therapy
Description: Daily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
Study NCT04783090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: bispecific peptide as a CaSR agonist and a functional OGP analogue
Study NCT05936697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fNIRS
Description: For fNIRS to be recorded by the wearable OctaMon+ system (Artinis Medical Systems, The Netherlands), two sources, each surrounded by four detectors positioned approximately 3 cm apart, will be placed on the scalp such that the two channels near the fissure on each side of the head are surrounded F3 and F4. Data will be sampled at 50 Hz.
Study NCT05936697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: For EEG to be recorded by the ANT eego rt8 amplifier (ANT Neuro, Hengelo, The Netherlands), electrodes will be placed at Fp1, F3, F4, Fz, Fpz, Cz, GND (ground), lower VEOG, and on the two earlobes (references). Data will be collected at 2,048 Hz.
Study NCT05936697 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Baseline Training
Description: In the sham condition, participants will receive visual feedback based on pre-recordings and/or other participants' recordings. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity within and across sessions.
Study NCT05349799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL RHA® 1
Description: During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will not receive any additional treatment.
Study NCT05349799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (needle)
Description: During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a needle. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5).